10.9% Surge in Viral Inactivation Market Growth: Forecasted to Cross $8.28 Billion by 2029

 The Business Research Company’s report on the Viral Inactivation Market provides insights into the global market size, growth rate, regional distribution, competitive landscape, key segments, emerging trends, and strategic opportunities.

 
 How have key drivers contributed to the rapid growth of the viral inactivation market?
 Growing instances of various infectious diseases are expected to propel the growth of the viral inactivation market, going forward. Infectious diseases refer to the conditions that transmit from one individual to another, via polluted foods and beverages, and through pathogens such as viruses, bacteria, fungi, and parasites. Viral inactivation is widely applicable in human disease-control programs to inactivate viruses using physical and chemical disinfectants to prevent the spread of contagious viral infections, resulting in the growth of the viral inactivation market. For instance, in March 2024, according to the Centers for Disease Control and Prevention, a US-based national public health agency of the United States, the number of cases of tuberculosis increased from 8,320 in 2022 to 9,615 in 2023, an increase of 1,295 cases. The rate also increased from 2.5 per 100,000 persons in 2022 to 2.9 in 2023. Therefore, the growing instances of various infectious diseases are driving the growth of the viral inactivation market.
 
 Access Your Free Sample of the Global Viral Inactivation Market Report — Get Insights Now!
 https://www.thebusinessresearchcompany.com/sample.aspx?id=10401&type=smp
 
 How has the viral inactivation market size evolved, and what are the latest forecasts for its expansion?
 The viral inactivation market size has grown strongly in recent years. It will grow from$5.01 billion in 2024 to $5.48 billion in 2025 at a compound annual growth rate (CAGR) of 9.4%. The growth in the historic period can be attributed to global air traffic growth, enhanced navigation capabilities, commercial aviation expansion, airline cost savings, improved flight safety, reduction in pilot workload
 
 The viral inactivation market size is expected to see rapid growth in the next few years. It will grow to “$8.28 billion in 2029 at a compound annual growth rate (CAGR) of 10.9%. The growth in the forecast period can be attributed to autonomous flight development, next-generation aircraft designs, efforts for sustainable aviation, urban air mobility (uam), increasing demand for aircraft. Major trends in the forecast period include integration of advanced avionics, implementation of artificial intelligence, human-machine interface (hmi) innovations, retrofitting existing aircraft, global navigation satellite system (gnss) integration.
 
 Gain Exclusive Market Insights — Customize Your Research Report Today For Fast Delivery!
 https://www.thebusinessresearchcompany.com/customise?id=10401&type=smp
 
 Which major companies dominate the viral inactivation market?
 Major companies operating in the viral inactivation market include Merck & Co. Inc., Sartorius AG, Texcell SA, SGS SA, Charles River Laboratories Inc., Clean Cells SAS, Rad Source Technologies, WuXi AppTec, Sigma-Aldrich Co. LLC, Thermo Fisher Scientific Inc., Macopharma, Cerus Corporation, TERUMO BCT INC., Shandong Weigao Group Medical Polymer Co. Ltd., Pall Corporation And Eurofins Scientific, General Electric Company, Cytiva, Mettler Toledo, Viral Inactivated Plasma Systems SA, Eurofins Scientific SE, Lonza Group AG, Avantor Inc., Bio-Rad Laboratories Inc., F. Hoffmann-La Roche AG, Fujifilm Holdings Corporation, Pfizer Inc., Novartis AG, Gilead Sciences Inc., Johnson & Johnson Private Limited
 
 What trends will shape the future of the vinyl acetate monomer market?
 The increasing use of technologically advanced processes is a key trend gaining popularity in the viral inactivation market. Companies operating in the viral inactivation market are adopting technologically advanced processes to sustain their position in the market. For instance, in March 2022, WuXi Advanced Therapies, a wholly owned subsidiary of WuXi AppTec, a China-based, biopharmaceutical company, launched Tetracycline-Enabled Self-Silencing Adenovirus (TESSA) Technology. This cutting-edge technology has enabled, the approval of new therapies by conducting all assay formulation, biosafety, viral clearance, product release, and testing, done simultaneously, in-house. This technique is a novel innovative method for producing adeno-associated virus (AAV) at Good Manufacturing Practices (GMP) grade without the need for transfection.
 
 Which region dominates the viral inactivation market, and what factors contribute to its leadership?
 North America was the largest region in the viral inactivation market in 2024. Asia-pacific is expected to be the fastest-growing region in the global viral inactivation market during the forecast period. The regions covered in the viral inactivation market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
 
 Order Your Report Now For Swift Delivery
 https://www.thebusinessresearchcompany.com/report/viral-inactivation-global-market-report
 
 How is the viral inactivation market segmented, and which segment holds the largest share?
 The viral inactivation market covered in this report is segmented –
 
 1) By Product: Kits And Reagents, Systems, Services
 2) By Method: Solvent Detergent Method, pH Adjustment Method, Pasteurization, Other Methods
 3) By Application: Vaccines And Therapeutics, Tissues And Tissue Products, Blood And Blood Products, Other Applications
 4) By End User: Pharmaceutical And Biotechnology Companies, Contract Research Organizations, Blood Banks, Hospital, Academic Research Institutes, Other End Users
 
 Subsegments:
 1) By Kits And Reagents: Viral Inactivation Kits, PCR Reagents, Antibodies and Enzymes
 2) By Systems: Automated Viral Inactivation Systems, Batch Viral Inactivation Systems, Continuous Flow Systems
 3) By Services: Viral Testing Services, Validation Services, Consulting Services
 
 Purchase The Exclusive Report Now To Unlock Valuable Market Insights:
 https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=10401
 
 How is the viral inactivation market defined?
 Viral inactivation refers to the process of inactivation of viral contamination by exposing the bioprocess fluid to environments that denature the viral protein yet retain the active ingredient of the product. Viral inactivation is most commonly used in blood plasma processing and monoclonal antibody processing.
 
 About The Business Research Company:
 
 With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead. 
 
 Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
 
 Contact Us:
 
 The Business Research Company
 
 https://thebusinessresearchcompany.com/
 
 Europe: +44 207 1930 708
 
 Asia: +91 88972 63534
 
 Americas: +1 315 623 0293
 
 Email: info@tbrc.info
 
 
 Follow Us On:
 
 LinkedIn: https://in.linkedin.com/company/the-business-research-company